About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Sofra™
RNA Vaccines and Therapeutics
Autoimmune Disease
Scientific Background
Chroma™
Clinical Trials
Publications & Events
Investor Centre
Share Price
ASX Announcements
Presentations & Interviews
Annual Reports
Financial Reports
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Investor Centre
Investor Centre
>
Presentations & Interviews
Share Price
ASX Announcements
Presentations & Interviews
Annual Reports
Financial Reports
Corporate Governance
Investor Fact Sheet
Share Registry Information
Presentations & Interviews
19-Nov-2024
Noxopharm 2024 AGM Corporate Presentation
3-Sep-2024
Ausbiz interview on brain cancer research
20-Aug-2024
Proactive Investors interview: First trial for SOF-SKN™
19-Aug-2024
Ausbiz interview on HERACLES trial
14-Jun-2024
Chief Executive Officer Letter
16-Nov-2023
Noxopharm 2023 AGM Corporate Presentation
16-Oct-2023
Noxopharm talks partnership with Hudson Institute of Medical Research
22-May-2023
Noxopharm hails new Sofra™ drug inflammation results
17-Nov-2022
Noxopharm 2022 AGM Corporate Presentation
4-Oct-2022
Ausbiz interview regarding pancreatic cancer research
14-Sep-2022
Noxopharm reveals encouraging new pancreatic cancer preclinical study data
7-Jun-2022
Noxopharm New Corporate Presentation June 2022
